Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin, a big step toward applying for regulatory approval this year. Report
Register for the first-ever Pharmaceutical Multi-Channel Marketing Strategy Conference, an industry-specific meeting featuring top leaders and latest trends in the pharmaceutical space. The conference, hosted by Q1 Productions, will feature sessions and interactive panel discussions addressing top concerns within pharmaceutical marketing, including the most effective marketing techniques to increase e-prescribing, the impact of marketing and shifting healthcare models, and developing content for increasingly complex channels. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!